Are there any emerging pharmacotherapies beyond orexin antagonists currently undergoing FDA clinical trials for severe treatment resistant insomnia?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Are there any emerging pharmacotherapies beyond orexin antagonists currently undergoing FDA clinical trials for severe treatment resistant insomnia?
3 real searches · 1 real-search pass
emerging pharmacotherapies treatment-resistant insomnia clinical trials 2025 2026 non orexin drugs phase 2Google ↗
OBSERVED
ClinicalTrials.gov severe treatment resistant insomnia pharmacologic trial novel drug insomnia 2026Google ↗
OBSERVED
FDA clinical trials insomnia novel pharmacotherapy GABA melatonin histamine 2025 2026Google ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
emerging pharmacotherapies treatment-resistant insomnia clinical trials 2025 2026 non orexin drugs phase 2 Google ↗
ClinicalTrials.gov severe treatment resistant insomnia pharmacologic trial novel drug insomnia 2026 Google ↗
FDA clinical trials insomnia novel pharmacotherapy GABA melatonin histamine 2025 2026 Google ↗
- Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance – Wed, 10/07/2026 · investors.seaporttx.com
- Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. · pubmed.ncbi.nlm.nih.gov
- Insomnia Drug Pipeline: 10 Assets by Phase · douglasinsights.com
- Emerging and upcoming therapies in insomnia - :: TCP :: Translational and Clinical Pharmacology · tcpharm.org
- Efficacy and safety of a selective partial agonist for nociception/orphanin-FQ peptide (NOP) receptors in patients with insomnia disorder. · pubmed.ncbi.nlm.nih.gov
- Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder · pmc.ncbi.nlm.nih.gov
- The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia. · pubmed.ncbi.nlm.nih.gov
- Evaluating Efficacy and Safety of CBD TPM Capsules for Use in Insomnia · centerwatch.com
- Cannabidiol (CBD) Capsule 75mg in Insomnia - Clinical Trials Registry · ichgcp.net
- Positive interim analysis advances Avecho Phase III insomnia program · prnewswire.com
- July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting · fda.gov
- insomnia reported no significant adverse effects, studies in subjects with withdrawal symptoms reported transient headache, nausea, and vertigo as common side effects with cases of hypotension that was “progressive” following second emideltide injection administered IV. Considering that the context of use may be for chronic intermittent use, safety for emideltide-related products is insufficiently characterized. In subjects treated for withdrawal symptoms any adverse effects may have been confou · fda.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
emerging pharmacotherapies treatment-resistant insomnia clinical trials 2025 2026 non orexin drugs phase 2 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
ClinicalTrials.gov severe treatment resistant insomnia pharmacologic trial novel drug insomnia 2026 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA clinical trials insomnia novel pharmacotherapy GABA melatonin histamine 2025 2026 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |